正常血清降钙素和大肿块甲状腺髓样癌的研究进展

doi:10.16139/j.1007-9610.2022.03.018

摘要/Abstract

摘要：

甲状腺髓样癌（medullary thyroid carcinoma, MTC）具有侵袭性强、较早出现淋巴结转移及远处转移的特点。在甲状腺肿瘤中,MTC侵袭程度仅次于未分化癌。血清降钙素是检测MTC最敏感的肿瘤标志物,并与肿瘤大小相关。然而,当肿瘤直径>1 cm时,部分MTC病人血清降钙素处于正常范围,给诊断带来困难。本文综述肿瘤直径>1 cm、血清降钙素正常的MTC研究进展。

关键词: 甲状腺髓样癌, 降钙素, 预测因素

Abstract:

The characteristics of medullary thyroid carcinoma (MTC) include strong invasiveness, early lymph node metastasis and distant metastasis. MTC is aggresive only less than anaplastic carcinoma in all thyroid malignancies. Serum calcitonin is the most sensitive tumor marker for detecting MTC, which correlates with tumor size. However, it is difficult to diagnose some MTC patients with tumor diameter greater than 1 cm and serum calcitonin negative. This review focuses on recent advances in study on MTC with diameter greater than 1 cm and serum calcitonin negative.

Key words: Medullary thyroid carcinoma, Calcitonin, Prediction

中图分类号:

R736.1

李瑞, 刘卓然综述, 严佶祺审校. 正常血清降钙素和大肿块甲状腺髓样癌的研究进展[J]. 外科理论与实践, 2022, 27(03): 271-275.

LI Rui, LIU Zhuoran, YAN Jiqi. Progress of study on medullary thyroid carcinoma with serum calcitonin-negative and large mass[J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 271-275.

图/表 1

表1

参考文献 42

[1]	Viola D, Elisei R. Management of medullary thyroid cancer[J]. Endocrinol Metab Clin North Am, 2019, 48(1):285-301. doi: 10.1016/j.ecl.2018.11.006 URL
[2]	Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma[J]. Thyroid, 2015, 25(6):567-610. doi: 10.1089/thy.2014.0335 URL
[3]	Ceolin L, Duval MADS, Benini AF, et al. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives[J]. Endocr Relat Cancer, 2019, 26(9):R499-R518.
[4]	Samà MT, Rossetto Giaccherino R, Gallo M, et al. Clinical challenges with calcitonin-negative medullary thyroid carcinoma[J]. J Cancer Res Clin Oncol, 2016, 142(9):2023-2029. doi: 10.1007/s00432-016-2169-5 URL
[5]	Liu Y, Yuan L, Yang D, et al. Serum calcitonin negative mixed medullary-follicular carcinoma initially diagnosed as medullary thyroid carcinoma by fine-needle aspiration cytology: a case report and review of the literatures[J]. Diagn Cytopathol, 2018, 46(8):690-693. doi: 10.1002/dc.23924 URL
[6]	Kartal Baykan E, Erdoan M. Basal and pentagastrin-stimulated calcitonin cut-off values in diagnosis of preoperative medullary thyroid cancer[J]. Turk J Med Sci, 2021, 51(2):650-656. doi: 10.3906/sag-2003-182 pmid: 33128357
[7]	Filimon S, Payne RJ, Black MJ, et al. Calcitonin secretory index and unsuspected nodal disease in medullary thyroid carcinoma[J]. Endocr Pract, 2018, 24(5):460-467. doi: 10.4158/EP-2017-0236 pmid: 29847167
[8]	王宇, 田文, 嵇庆海, 等. 甲状腺髓样癌诊断与治疗中国专家共识(2020版)[J]. 中国实用外科杂志, 2020, 40(9):1012-1020.
[9]	Haddad RI, Nasr C, Bischoff L, et al. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018[J]. J Natl Compr Canc Netw, 2018, 16(12):1429-1440. doi: 10.6004/jnccn.2018.0089 URL
[10]	Allelein S, Ehlers M, Morneau C, et al. Measurement of basal serum calcitonin for the diagnosis of medullary thyroid cancer[J]. Horm Metab Res, 2018, 50(1):23-28. doi: 10.1055/s-0043-122237 URL
[11]	Sobol RE, Memoli V, Deftos LJ. Hormone-negative, chromogranin A-positive endocrine tumors[J]. N Engl J Med, 1989, 320(7):444-447. doi: 10.1056/NEJM198902163200707 URL
[12]	Redding AH, Levine SN, Fowler MR. Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses[J]. Thyroid, 2000, 10(10):919-922. pmid: 11081258
[13]	Bockhorn M, Frilling A, Rewerk S, et al. Lack of eleva-ted serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma[J]. Thyroid, 2004, 14(6):468-470. doi: 10.1089/105072504323150813 URL
[14]	Sand M, Gelos M, Sand D, et al. Serum calcitonin negative medullary thyroid carcinoma[J]. World J Surg Oncol, 2006, 4:97. doi: 10.1186/1477-7819-4-97 URL
[15]	Giovanella L, Crippa S, Cariani L. Serum calcitonin-negative medullary thyroid carcinoma: role of CgA and CEA as complementary markers[J]. Int J Biol Markers, 2008, 23(2):129-131. doi: 10.1177/172460080802300212 URL
[16]	Dora JM, Canalli MH, Capp C, et al. Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature[J]. Thyroid, 2008, 18(8):895-899. doi: 10.1089/thy.2007.0231 URL
[17]	Alapat DV, Ain KB, Sloan DA, et al. Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma[J]. Endocrine, 2011, 39(2):148-152. doi: 10.1007/s12020-010-9433-2 pmid: 21243446
[18]	Frank-Raue K, Machens A, Leidig-Bruckner G, et al. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma[J]. Thyroid, 2013, 23(3):294-300. doi: 10.1089/thy.2012.0236 pmid: 22946486
[19]	Brutsaert EF, Gersten AJ, Tassler AB, et al. Medullary thyroid cancer with undetectable serum calcitonin[J]. J Clin Endocrinol Metab, 2015, 100(2):337-341. doi: 10.1210/jc.2014-3095 pmid: 25490273
[20]	Zhou Q, Yue S, Cheng Y, et al. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin[J]. Exp Toxicol Pathol, 2017, 69(8):575-579. doi: 10.1016/j.etp.2017.05.003 URL
[21]	Cipri C, Vescini F, Torresan F, et al. An unusual case of medullary thyroid carcinoma and a revision of current li-terature[J]. Endocr Metab Immune Disord Drug Targets, 2019, 19(2):226-229. doi: 10.2174/1871530319666181220165350 URL
[22]	Murphy DC, Johnson SJ, Aspinall S. Calcitonin-negative medullary thyroid carcinoma: the “triple-negative” pheno-type[J]. Ann R Coll Surg Engl, 2020, 102(3):e63-e66.
[23]	Jingzhu Z, Xiangqian Z, Ming G, et al. Clinical challenges with calcitonin-negative medullary thyroid carcinoma: three case reports and a review of the literature[J]. Ann R Coll Surg Engl, 2022, 104(3):221-230.
[24]	Kim SJ, Yun HJ, Shin SJ, et al. Serum calcitonin-negative medullary thyroid carcinoma: a case series of 19 patients in a single center[J]. Front Endocrinol (Lausanne), 2021, 12:747704. doi: 10.3389/fendo.2021.747704 URL
[25]	Montgomery G, Collins L, Coghlin C, et al. Calcitonin negative medullary thyroid cancer in ectopic thyroid tissue: a rare diagnosis in an unusual location[J]. BMJ Case Rep, 2020, 13(8):e236865. doi: 10.1136/bcr-2020-236865 URL
[26]	Leboeuf R, Langlois MF, Martin M, et al. “Hook effect” in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature[J]. J Clin Endocrinol Metab, 2006, 91(2):361-364. doi: 10.1210/jc.2005-1429 URL
[27]	Fernández-Ferreira R, De la Peña-López IR, Zamudio-Coronado KW, et al. Calcitonin-negative neuroendocrine carcinoma of the thyroid gland: case report and literature review[J]. Case Rep Oncol, 2021, 14(1):112-122. doi: 10.1159/000510807 pmid: 33776692
[28]	Leboulleux S, Baudin E, Young J, et al. Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma[J]. Eur J Endocrinol, 1999, 140(3):187-191. doi: 10.1530/eje.0.1400187 pmid: 10216512
[29]	Konstantinidis A, Stang M, Roman SA, et al. Surgical management of medullary thyroid carcinoma[J]. Updates Surg, 2017, 69(2):151-160. doi: 10.1007/s13304-017-0443-y pmid: 28409442
[30]	Hassan A, Siddique M, Riaz S, et al. Medullary thyroid carcinoma: prognostic variables and tumour markers affecting survival[J]. J Ayub Med Coll Abbottabad, 2018, 30(4):S627-S632.
[31]	Parmer M, Milan S, Torabi A. Calcitonin-negative neuroendocrine tumor of the thyroid[J]. Int J Surg Pathol, 2017, 25(2):191-194. doi: 10.1177/1066896916670989 pmid: 27658647
[32]	Giovanella L, Garo ML, Ceriani L, et al. Procalcitonin as an alternative tumor marker of medullary thyroid carcinoma[J]. J Clin Endocrinol Metab, 2021, 106(12):3634-3643. doi: 10.1210/clinem/dgab564 pmid: 34382653
[33]	Karagiannis AK, Girio-Fragkoulakis C, Nakouti T. Procalcitonin: a new biomarker for medullary thyroid cancer? a systematic review[J]. Anticancer Res, 2016, 36(8):3803-3810. pmid: 27466480
[34]	Vargas CVF, Ceolin L, Scheffel RS, et al. The tissue expression pattern of CA 19.9 is associated with oncological features in medullary thyroid carcinoma[J]. Endocrine, 2020, 70(3):544-551. doi: 10.1007/s12020-020-02377-3 URL
[35]	Elisei R, Lorusso L, Piaggi P, et al. Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer[J]. Eur J Endocrinol, 2015, 173(3):297-304. doi: 10.1530/EJE-15-0304 URL
[36]	Liu MJ, Liu ZF, Hou YY, et al. Ultrasonographic characteristics of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma[J]. Oncotarget, 2017, 8(16):27520-27528. doi: 10.18632/oncotarget.15897 URL
[37]	Tripathy S, Aggrawal S, Subudhi K, et al. Calcitonin-negative neuroendocrine tumor of the thyroid on 68Ga DOTANOC PET-CT[J]. Clin Nucl Med, 2019, 44(9):e546-e547.
[38]	Naswa N, Sharma P, Suman Kc S, et al. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT[J]. Nucl Med Commun, 2012, 33(7):766-774. doi: 10.1097/MNM.0b013e3283541157 URL
[39]	Trimboli P, Giovanella L, Crescenzi A, et al. Medullary thyroid cancer diagnosis: an appraisal[J]. Head Neck, 2014, 36(8):1216-1223. doi: 10.1002/hed.23449 URL
[40]	Trimboli P, Cremonini N, Ceriani L, et al. Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study[J]. Clin Endocrinol (Oxf), 2014, 80(1):135-140. doi: 10.1111/cen.12234 URL
[41]	Salvatore D, Santoro M, Schlumberger M. The importance of the RET gene in thyroid cancer and therapeutic implications[J]. Nat Rev Endocrinol, 2021, 17(5):296-306. doi: 10.1038/s41574-021-00470-9 pmid: 33603219
[42]	Thomas CM, Asa SL, Ezzat S, et al. Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines[J]. Curr Oncol, 2019, 26(5):338-344. doi: 10.3747/co.26.5539 pmid: 31708652

参考文献	性别	年龄（岁）	肿瘤直径（cm）	随访时间	预后	降钙素（免疫组织化学）	术后降钙素	术后癌胚抗原	细针穿刺	转染期间重排基因
Samà等^[4]	男	60	3.8	10年	无复发	弱阳性	未升高	未升高	/	阴性
	男	53	1.2	3年	无复发	/	未升高	未升高	/	阳性
	男	62	4.5	1年	无复发	弱阳性	未升高	未升高	/	阴性
Sobol等^[11]	女	82	2.0	23个月	6个月后转移,23个月后死亡	阴性	未升高	未升高	/	/
Redding等^[12]	女	31	4.5	43个月	无复发	强阳性	未升高	未升高	恶性	/
Bockhorn等^[13]	女	50	2.0	5年	无复发	弱阳性	/	/	/	阴性
Sand等^[14]	女	73	>4.0	6周	死于肺转移和脑转移	弱阳性	/	/	/	/
Giovanella等^[15]	女	43	3.6	2年	无复发	强阳性	未升高	未升高	恶性	/
Dora等^[16]	男	43	1.7	/	/	强阳性	/	/	恶性	阴性
Alapat等^[17]	女	16	3.0	20个月	无复发	强阳性	未升高	未升高	MTC	/
Frank-Raue等^[18]	男	70	8.0	2.25年	伴肺转移	弱阳性	未升高	未升高	/	阴性
	女	50	2.0	12.5年	10年后复发	弱阳性	未升高	升高	MTC	阳性
	男	47	3.0	1.5年	无复发	强阳性	未升高	未升高	/	阴性
	女	53	4.5	1.75年	伴远处转移	强阳性	未升高	未升高	MTC	阳性
	男	45	1.8	1.75年	死于肺转移	弱阳性	升高	未升高	/	阳性
	女	45	5.5	3年	死于肺转移	强阳性	未升高	未升高	/	阳性
Brutsaert等^[19]	女	39	2.6	/	/	强阳性	/	/	恶性	阴性
Murphy等^[22]	女	24	3.5	3年	无复发	阴性	未升高	未升高	/	阴性
Jingzhu等^[23]	男	66	7.0	2个月	死于局部复发	强阳性	/	/	/	/
	女	65	1.48	15个月	死于肝、脑、肺转移	弱阳性	/	/	/	/
Montgomery等^[25]	男	45	2.3	/	/	阴性	/	/	NET	/